Hodgkin's disease presenting at the elbow.
Explore the source record for details and available documents.
Biomedical subjects
Publications and source records attributed to P V Sacks.
Explore the source record for details and available documents.
The rate of hemoglobin repletion in iron-deficient rats was used to measure the bioavailability of several elemental iron powders added to an iron-free nutritionally balanced chow. We used ferrous sulfate as a standard, highly bioavailable control. Of the several powders, carbonyl iron demonstrated the highest bioavailability. Testing elemental iron powders in human diets seems appropriate.
A patient in whom lymphocyte-depleted Hodgkin's disease and multiple myeloma were diagnosed simultaneously is reported. There was no prior history of irradiation or chemotherapy, the significance of which is discussed in relation to previously documented patients with Hodgkin's disease and myeloma.
Explore the source record for details and available documents.
Severe thrombocytopenia developed in a patient with rheumatoid arthritis during gold therapy. Increased numbers of marrow megakaryocytes, shortened 51Cr-labeled platelet survival and platelet phagocytosis by splenic macrophages indicated that thrombocytopenia was due to excessive platelet destruction. Aurothiomalate disodium antigenicity was demonstrated by increased lymphocyte blastogenesis, and accentuation of blood and splenic leukocyte migration in the presence of the gold salt. In vitro splenic immunoglobulin G (IgG) production was markedly increased, and a significant portion of the culture-produced IgG attached specifically to homologous platelets and platelet membranes. Serum antiplatelet antibodies could not be demonstrated, nor could it be shown that gold enhanced the binding of splenic-synthesized IgG to platelets. The data indicate an immunologic mechanism for gold-associated thrombocytopenia and permit speculation as to possible ways in which unidentified antigens may be involved in the pathogenesis in idiopathic thrombocytopenic purpura.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.